High-Intensity Interval Training and Moderate-Intensity Continuous Training in Adults with Crohn's Disease : A Pilot Randomised Controlled Trial by Tew, Garry et al.
This is a repository copy of High-Intensity Interval Training and Moderate-Intensity 
Continuous Training in Adults with Crohn's Disease : A Pilot Randomised Controlled Trial.




Tew, Garry, Leighton, Dean, Carpenter, Roger et al. (8 more authors) (2019) High-Intensity
Interval Training and Moderate-Intensity Continuous Training in Adults with Crohn's 






This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence 
allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the 
authors for the original work. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
brought to you by COREView metadata, citation and similar papers at core.ac.uk
provided by White Rose Research Online
RESEARCH ARTICLE Open Access
High-intensity interval training and
moderate-intensity continuous training in
adults with Crohn’s disease: a pilot
randomised controlled trial
Garry A. Tew1* , Dean Leighton2, Roger Carpenter3, Simon Anderson4, Louise Langmead5, John Ramage6,
James Faulkner7, Elizabeth Coleman8, Caroline Fairhurst8, Michael Seed3 and Lindsay Bottoms9
Abstract
Background: This study assessed the feasibility and acceptability of two common types of exercise training—high-
intensity interval training (HIIT) and moderate-intensity continuous training (MICT)—in adults with Crohn’s disease (CD).
Methods: In this mixed-methods pilot trial, participants with quiescent or mildly-active CD were randomly assigned 1:
1:1 to HIIT, MICT or usual care control, and followed up for 6months. The HIIT and MICT groups were offered three
exercise sessions per week for the first 12 weeks. Feasibility outcomes included rates of recruitment, retention, outcome
completion, and exercise attendance. Data were collected on cardiorespiratory fitness (e.g., peak oxygen uptake),
disease activity, fatigue, quality of life, adverse events, and intervention acceptability (via interviews).
Results: Over 17months, 53 patients were assessed for eligibility and 36 (68%) were randomised (47% male; mean age
36.9 [SD 11.2] years); 13 to HIIT, 12 to MICT, and 11 to control. The exercise session attendance rate was 62% for HIIT
(288/465) and 75% for MICT (320/429), with 62% of HIIT participants (8/13) and 67% of MICT participants (8/12)
completing at least 24 of 36 sessions. One participant was lost to follow-up. Outcome completion rates ranged from 89
to 97%. The mean increase in peak oxygen uptake, relative to control, was greater following HIIT than MICT (2.4 vs. 0.7
mL/kg/min). There were three non-serious exercise-related adverse events, and two exercise participants experienced
disease relapse during follow-up.
Conclusions: The findings support the feasibility and acceptability of the exercise programmes and trial procedures. A
definitive trial is warranted. Physical exercise remains a potentially useful adjunct therapy in CD. [ID: ISRCTN13021107].
Keywords: Inflammatory bowel disease, Exercise therapy, Randomised controlled trial
Background
Regular exercise training has been recommended as an
adjunct therapy for people with Crohn’s disease (CD)
[1–3] because of its potential beneficial effects on physical
fitness, mental health, and disease-related factors such as
fatigue, bone mineral loss and inflammation [4–6]. How-
ever, empirical evidence on the effects of exercise training
in CD is sparse, with only a handful of intervention studies
[7–11], some of which have methodological limitations,
such as short follow-up, no control group, and a small
sample size. Among adults with other chronic inflamma-
tory diseases, a traditional model of exercise prescription
has been moderate-intensity continuous training (MICT;
e.g. 30–60min of moderate-intensity continuous endura
nce-type exercise such as swimming, cycling or running
performed 3–5 times per week) [12], but a growing body
of evidence indicates that high-intensity interval training
(HIIT; e.g. 0.5–4min bouts of vigorous exercise inter-
spersed by periods of passive or active recovery) is a more
time-efficient exercise strategy, eliciting similar or even
superior cardio-metabolic adaptations compared to MICT,
at least when compared on a work-matched basis [13–16].
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There has only been one published study investigating
HIIT in CD patients to date [17], which showed that a sin-
gle session of cycle-based HIIT was well tolerated and did
not markedly increase pro-inflammatory cytokines (e.g.,
TNF-α) in a group of 15 teenagers. A greater understand-
ing of the feasibility, acceptability and effects of different
types of exercise training is needed to support the devel-
opment evidence-based exercise guidelines and promotion
strategies that are specific to CD.
We hypothesised that supervised endurance exercise
training (either as HIIT or MICT) is a safe and effective
strategy for improving cardiorespiratory fitness, fatigue,
quality of life and mental health in people with CD. Be-
fore embarking on a full-scale randomised controlled
trial to test this hypothesis, we conducted a pilot trial to
address several areas of uncertainty. For example, the
possibility that many potential participants would be of
working age and have disease-specific barriers to exer-
cise (e.g., fatigue [18]) raised questions about the ability
to recruit and retain individuals with CD to a clinical
trial of supervised exercise training. Hence, the main
aims of the Exercise for Adults with Crohn’s disease
Trial (EXACT) study were to determine the acceptability
and potential benefits and harms of HIIT and MICT in
adults with quiescent or mildly-active CD, and the feasi-
bility of conducting a full-scale trial.
Methods
Study design and setting
A full description of the methods has been published
[19]. The study was a multi-centre, three-arm, parallel-
group, pilot randomised controlled trial. Participants
were randomised 1:1:1 to receive usual care, usual care
plus HIIT or usual care plus MICT. Study assessments
were conducted at baseline and at 3 and 6months after
randomisation. Recruitment was from three hospital
trusts in England: Guy’s and St Thomas’ NHS Founda-
tion Trust, Barts Health NHS Trust, and Hampshire
Hospitals NHS Foundation Trust. The exercise pro-
grammes were delivered in the exercise science facilities
of the University of East London and the University of
Winchester. Data management and statistical analysis
took place at York Trials Unit, University of York. Ethics
approval was granted by the Camden and Kings Cross
Research Ethics Committee (reference 15/LO/1804), and
all participants provided written informed consent be-
fore enrolment. The trial was registered prospectively
(ISRCTN13021107).
Participants
We included male and female patients between 16 and
65 years of age with a clinical diagnosis of CD. Patients
had to have a stool calprotectin of < 250 μg/g, stable
medication (> 4 weeks), and quiescent or mildly-active
disease, as indicated by a Crohn’s Disease Activity Index
(CDAI) of < 150 or 150–219, respectively. Exclusion cri-
teria were: contraindication to exercise testing or train-
ing [20], coexistent serious autoimmune disease (e.g.
rheumatoid arthritis or systemic sclerosis), pregnant,
planned pregnancy or major surgery within the first 3
months after randomisation, poor tolerability of vene-
puncture or inadequate access for venous blood sam-
pling, and current participation in > 90min/week of
purposeful exercise (e.g. cycling, swimming or running)
or another clinical trial.
Randomisation and allocation concealment
A statistician at York Trials Unit managed the random-
isation process. Following baseline assessment, a re-
search assistant emailed the statistician for notification
of the participant’s group allocation. Participants were
randomly assigned 1:1:1 to one of the three study groups
using a computer-generated randomisation schedule strati-
fied by centre and baseline disease status (inactive [CDAI
< 150] or mild [CDAI 150–219]) using randomly permuted
blocks of sizes 3 and 6. The block sizes and allocation se-
quence were not disclosed to ensure concealment.
Interventions
All three groups received usual care, which comprised
evidence-based medical treatment optimisation. Partici-
pants allocated to usual care did not receive any super-
vised exercise or exercise advice as part of the trial;
however, following the final study assessment they were
offered a telephone-based consultation with a research
assistant who discussed their individual facilitators/bar-
riers to exercise, and provided guidance on incorporat-
ing physical activity into their lifestyle.
Participants allocated to the HIIT and MICT groups
were invited to complete three supervised exercise ses-
sions per week for 12 consecutive weeks, commencing
the week following their baseline assessment and ran-
domisation. Reimbursement was provided for travel ex-
penses. All exercise was undertaken on a leg cycle
ergometer (Lode Corival or SRM Ergometer), with each
session comprising a 5-min warm-up at 15% of peak
power output (Wpeak; determined during the baseline
cardiopulmonary exercise test), a main conditioning
phase, and then a 3-min cool-down at 15% Wpeak. For
HIIT, the conditioning phase involved ten 1-min bouts
at 90% Wpeak, interspersed with 1-min bouts at 15%
Wpeak (total session duration = 28min), whereas for
MICT it involved 30min at 35% Wpeak (total session
duration = 38min). Heart rate (Polar FT1, Polar Electro,
Kempele, Finland), differential ratings for central (i.e.
cardiopulmonary sensations) and leg exertion (RPE-C
and RPE-L, respectively; Borg CR-10 scale [21]), and
general affective valence (i.e. pleasure and displeasure;
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11-point feeling scale) were recorded at regular intervals
during each session. The feeling scale data will be pub-
lished elsewhere. Incremental cycle exercise testing to
maximum volitional exertion was performed in the final
sessions of weeks 4 and 8 to re-calculate Wpeak and de-
termine if the power output of the upcoming exercise
sessions needed to be changed.
After the initial 12-week supervised training period, all
exercise group participants were encouraged to continue
a similar exercise regime in their own home or commu-
nity setting without the support of the trial team.
Feasibility and acceptability outcomes
Trial feasibility outcomes included rates of recruitment,
retention, and outcome completion. Barriers and facilita-
tors to recruitment were also identified using a standar-
dised questionnaire [22], which was completed by trial
staff who had a responsibility for recruitment. The ac-
ceptability of the exercise programmes was assessed
using group preference data (assessed before randomisa-
tion), rates of session attendance and completion, a
measure of exercise enjoyment completed at 3 months
after randomisation (Physical Activity Enjoyment Scale,
PACES [23]), and participant feedback via telephone in-
terviews conducted after the 6-month assessments. The
safety of the exercise programmes was also assessed by ex-
ploring rates of disease relapse at 3months, the number
and type of adverse events, drop-out rates, and reasons for
withdrawal in each group. Relapse was defined as an in-
crease in CDAI of ≥100 points to a score ≥ 150 [24].
We pre-specified that this pilot trial would be deemed
successful and lead to the development of a proposal for
a full-scale trial if: (i) at least one of the exercise pro-
grammes was shown to be acceptable, based principally
on participant feedback (i.e. interview data) and exercise
session attendance data (acceptable attendance defined
as at least 67% of participants completing at least 24 of
the 36 sessions); (ii) at least 24 patients being recruited
within 12months, and; (iii) complete data on cardiore-
spiratory fitness, CDAI, and quality of life at 3 months
for at least 67% of participants.
Behaviour, fitness and health outcomes
The following outcome measures were assessed in all
participants at baseline and 3months after randomisa-
tion: body mass, stature, waist circumference, blood
pressure, resting heart rate, cardiorespiratory fitness
(ventilatory threshold and peak oxygen uptake recorded
during incremental cycle ergometer testing to maximum
volitional exertion), disease status (CDAI), intestinal in-
flammation (faecal calprotectin), and blood markers of
inflammation (T lymphocyte subsets [Th1/Th2/Th17]
and various cytokines including IL-6, IL-10, TNF-α and
C-reactive protein; data to be published elsewhere).
Standard questionnaires were also administered at base-
line and 3 and 6months after randomisation, including
the Inflammatory Bowel Disease Quality of Life Question-
naire (IBDQ [25]), EuroQol EQ-5D-5 L (to measure
health-related quality of life, [26]), IBD Fatigue Scale [27],
Hospital and Anxiety Depression Scale (HADS [28]), and
International Physical Activity Questionnaire-long (IPAQ
[29]). (Please note that the published trial protocol con-
tains a typographical error in that it states that the short
version of the IPAQ would be administered).
Sample size
Following sample size guidelines for pilot studies [30],
we aimed to have at least 12 participants in each group
complete the study. To allow for up to 20% attrition, an
overall target of 45 participants was used (15 per group).
Blinding
Due to the nature of the trial, blinding of participants
and intervention facilitators to group allocation was not
possible. Questionnaires were completed by participants
independently and checked by a researcher for com-
pleteness. Anthropometric, cardiorespiratory fitness and
disease activity outcomes were assessed by researchers
blinded to group allocation. Participants were asked not
to disclose their allocation.
Statistical analysis
Data from paper case report forms were entered and
checked for missing and invalid values in Microsoft
Excel® then imported into Stata v15 (StataCorp) for ana-
lysis. The flow of participants through the trial is pre-
sented in a CONSORT diagram (Fig. 1). Baseline data
are summarised descriptively by trial arm. The guidance
around analysing pilot studies states that no formal hy-
pothesis testing should be undertaken [31], and as such
quantitative outcome data are summarised using de-
scriptive statistics only, using the principles of intention
to treat. Exit interviews were analysed using qualitative
content analysis [32].
Results
Recruitment took place between May 2016 and September
2017, with all follow-up data collection completed by
March 2018. The trial was stopped at the end of the grant
funding interval, with the minimum recruitment target
having been achieved.
Recruitment, group allocation and participant
characteristics
Of 53 patients who were fully assessed for eligibility, 39 met
all eligibility criteria and 36 were randomised (Fig. 1). A me-
dian of 2 participants were recruited per month (range 1 to
6). The three sites recruited 19, 12 and five participants
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each. The most common reason for exclusion was having
active disease (n = 11). Interview data (analysed for n = 31;
summarised in Additional file 1) revealed that most partici-
pants were recruited via face-to-face approach in clinic,
with the most common reasons for enrolment being
potential health benefits (n = 20), altruistic motives (n = 12),
and it being seen as a good way to start an exercise regime
(n = 10). Five investigators provided feedback on barriers
and facilitators to recruitment (Additional file 2). These in-
vestigators and several participants suggested that recruit-
ment might have been easier had there been more exercise
venues. An investigator from the site with the least partici-
pants (Hampshire Hospitals NHS Foundation Trust; n = 5),
also stated that their recruitment was hampered by there
being fewer eligible patients than expected; most patients
attending their clinics had active disease.
Thirteen participants were allocated to HIIT, 12 to
MICT, and 11 to control (Fig. 1). Of the 27 partici-
pants who expressed a preference for a specific
group before allocation, 20 (74%) preferred HIIT, 6
(22%) MICT, and one (4%) control. Interviewees
recognised the need for a control group, and al-
though control participants were generally disap-
pointed with their allocation, they were willing to
complete the study. All but one control participant
reported maintaining their pre-trial exercise habits
during the follow-up period, with the remaining par-
ticipant explaining that they had started doing aer-
obic and strength training 3–4 times per week
shortly after randomisation. One exercise participant
said that they would have dropped out if they had
been allocated to control.
Allocated to MICT (n=12)
• Received MICT ( 1 session;
n=12)
Withdrew prior to randomisation (n=3)
• Patient uncontactable after 
screening (n=3)
Excluded (n=14)
• Planned major surgery (n=1)
• CDAI 220 (n=1)
• Faecal calprotectin 250mcg/g (n=10)
• Faecal calprotectin result unavailable (n=2)
Assessed for eligibility 
(n=53)
Recruited (n=39)
Allocated to HIIT (n=13)
• Received HIIT ( 1 session;
n=11)
• Did not receive HIIT (n=2: one 





















p Lost to 6-month follow-up (n=1)
• Reasons: uncontactable after 
3-month follow-up
Discontinued HIIT (n=1)
• Reasons: moved abroad
Cardiorespiratory fitness
12 analysed, 1 excluded
Disease activity
12 analysed, 1 excluded
Self-report questionnaires
11 analysed, 2 excluded
Exit interview







Allocated to control (n=11)
• Received usual care (n=11)
Lost to 6-month follow-up (n=0)
Discontinued MICT (n=0)
Lost to 6-month follow-up (n=0)
Cardiorespiratory fitness
12 analysed, 0 excluded
Disease activity
12 analysed, 0 excluded
Self-report questionnaires
12 analysed, 0 excluded
Exit interview
11 analysed, 1 excluded
Cardiorespiratory fitness
11 analysed, 0 excluded
Disease activity
11 analysed, 0 excluded
Self-report questionnaires
10 analysed, 1 excluded
Exit interview
10 analysed, 1 excluded
Randomised (n=36)
Fig. 1 Flow of participants through the trial
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Table 1 shows the participant characteristics at base-
line. The groups appear well balanced for the majority of
variables. Seventeen participants (47%) were male and
the mean age was 36.9 years (SD 11.2). A higher
proportion of participants were male in the HIIT (54%)
and control (64%) groups than the MICT group (25%).
Most participants were of white ethnicity (78%), had qui-
escent disease (89%), and were in paid employment
Table 1 Baseline demographics and clinical characteristics
HIIT (n = 13) MICT (n = 12) Control (n = 11) All (n = 36)
Age, years 37.0 (11.1) 38.5 (13.0) 35.0 (10.0) 36.9 (11.2)
Male sex, n (%) 7 (54) 3 (25) 7 (64) 17 (47)
White ethnicity, n (%) 10 (77) 11 (92) 7 (64) 28 (78)
Body mass, kg 76.2 (13.5) 63.8 (12.5) 69.8 (13.2) 70.1 (13.8)
Current smoker, n (%) 1 (8) 1 (8) 2 (18) 4 (11)
Employment status, n (%)
Working full- or part-time 9 (69) 10 (83) 9 (82) 28 (78)
Student 1 (8) 1 (8) 2 (18) 4 (11)
Other 3 (23) 1 (8) 0 (0) 4 (11)
CD duration, years 16.1 (11.9) 11.5 (10.9) 13.7 (9.8) 13.7 (10.8)
CD location, n (%)
Ileum 4 (31) 3 (25) 4 (36) 11 (31)
Colon 3 (23) 4 (33) 1 (9) 8 (22)
Ileum and colon 6 (46) 4 (33) 5 (46) 15 (42)
Missing 0 (0) 1 (8) 1 (9) 2 (6)
CD activity status, n (%)
Inactive 11 (85) 11 (92) 10 (91) 32 (89)
Mildly active 2 (15) 1 (8) 1 (9) 4 (11)
CDAI 74 (48) 55 (47) 73 (45) 67 (46)
Faecal calprotectin, μg/g 89 (72) 45 (40) 56 (55) 65 (59)
Medication for CD, n (%)
Immunosuppressants 8 (62) 5 (42) 4 (36) 17 (47)
Biologics 8 (62) 2 (17) 2 (18) 12 (33)
Oral 5-aminosalicylates 0 (0) 3 (25) 2 (18) 5 (14)
Analgesics 3 (23) 0 (0) 1 (9) 4 (11)
Antibiotics 1 (8) 0 (0) 1 (9) 2 (6)
Antidiarrheals 1 (8) 1 (8) 1 (9) 3 (8)
Previous surgery for CD, n (%)
Defunctioning ileostomy 1 (8) 0 (0) 1 (9) 2 (6)
Drainage of abscess 1 (8) 1 (8) 0 (0) 2 (6)
Excision of fistula 1 (8) 0 (0) 1 (9) 2 (6)
Right hemicolectomy 6 (46) 2 (17) 3 (27) 11 (31)
Small bowel resection 2 (15) 0 (0) 2 (18) 4 (11)
Left hemicolectomy 0 (0) 0 (0) 1 (9) 1 (3)
Panproctocolectomy and 1 (8) 0 (0) 1 (9) 2 (6)
ileostomy
Perianal surgery 1 (8) 0 (0) 1 (9) 2 (6)
Subtotal colectomy and primary anastomosis 0 (0) 0 (0) 1 (9) 1 (3)
Other 2 (15) 0 (0) 3 (27) 5 (14)
Data are presented as mean (SD) unless otherwise stated
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(78%). The mean time since diagnosis was 13.7 years,
ranging from 4months to 38.2 years. Twenty-six partici-
pants (72%) reported having slight-to-moderate fatigue
and eight (22%) reported having severe fatigue. There
were very few comorbidities, which included asthma
(n = 3), anaemia (n = 2), diabetes (n = 1), ankylosing
spondylitis (n = 1), and bipolar disorder (n = 1). The
most common medication used for CD was immuno-
suppressants (47%) and biologics (33%). The most
common previous surgery for CD was right hemico-
lectomy (n = 11).
Trial retention and assessment completion rates
No participants formally withdrew from the study, but
one HIIT participant was lost to the 6-month follow-up
(Fig. 1). At 3 months (i.e., intervention end-point), 34
(94%) participants completed the hospital visit, and 35
(97%) completed the university visit. At 6 months, 33
(92%) participants completed the postal questionnaire,
and 32 (89%) completed the telephone interview. The in-
terviewees stated that the logistics and content of the as-
sessment visits were acceptable (Additional file 1).
Exercise adherence, enjoyment and acceptability
Of the 465 and 429 exercise sessions that were offered
to HIIT and MICT participants, respectively, 288 (62%)
and 320 (75%) were attended, giving a combined attend-
ance rate of 68% (608/891). All 608 attended sessions
were completed as planned. The mean (SD) power out-
put used in the exercise sessions of weeks 1–4 and 9–12
were 148 (25) W and 173 (36) W respectively for the
HIIT group and 50 (14) W and 54 (13) W respectively
for the MICT group. The median (range) number of ses-
sions attended was 25 (0–36) and 25 (18–34) for the
HIIT and MICT groups, respectively. Eight (62%) of the
HIIT participants and eight (67%) of the MICT partici-
pants achieved the pre-specified attendance criterion of
at least 24 sessions. Two HIIT participants did not at-
tend a single exercise session: one due to illness, and the
other due to work and holiday commitments. Another
HIIT participant withdrew from the intervention after
completing 5 sessions due to moving abroad. The main
reasons for sessions being missed were work commit-
ments (25%, 72/286), illness (25%, 71/286 [only two of
which were CD-related]) and holiday (14%, 40/286) (data
from both exercise groups combined).
The interviews indicated mixed views about there be-
ing three sessions per week. Some participants (n = 12)
stated that this frequency was, or would have been (for
controls), difficult to adhere to, whereas others felt this
frequency to be achievable (n = 11) and necessary for im-
proving fitness (n = 6). Two participants indicated that
they would not have achieved this frequency had the ses-
sion times not been as flexible. Three other participants
stated that the frequency would have been more achiev-
able had weekend sessions also been offered.
The intensity of training completed by the HIIT par-
ticipants, based on data recorded at exercise interval 9
of 10, is summarised as follows: mean (SD) RPE-C = 5.1
(1.7) (i.e. ‘hard’), RPE-L = 5.5 (1.6) (i.e. ‘hard’) and heart
rate = 92% of maximum (5%). Corresponding values for
the MICT participants were: RPE-C = 2.9 (1.5) (i.e. ‘mod-
erate’), RPE-L = 3.3 (1.5) (i.e. ‘moderate’) and heart rate
68% of maximum (6%). None of the interviewees
thought that either training programme was too hard or
too easy. Two participants were initially concerned that
the HIIT might be too hard, but found that this did not
turn out to be the case.
All interviewees found cycling to be an acceptable
mode of exercise, with some recognising that it could be
carefully controlled and was suitable for a range of fit-
ness levels. However, two participants said that the seat
was uncomfortable. Six participants stated that they
would have also liked to try other exercise modes in-
cluding muscle-strengthening exercises (n = 4), running
(n = 1), and arm-cranking (n = 1). Another six partici-
pants stated that they were glad running was excluded,
with two participants explaining that it has previously
caused them to experience bowel urgency. Feedback on
other aspects of the exercise programmes (e.g. duration,
setting, provider) is summarised in Additional file 1. The
mean (SD) PACES score at 3 months (i.e. intervention
end-point) out of a possible 126 was 99.4 (12.9) for HIIT
and 101.3 (17.4) for MICT, equating to participants
reporting the exercise sessions as ‘enjoyable’.
Behaviour, fitness and health measures
Summary data for the behaviour, fitness and health mea-
sures are presented in Tables 2 and 3. The mean change
in peak oxygen uptake from baseline to 3 months, rela-
tive to control, was greater following HIIT than MICT
(+ 2.4 vs. + 0.7 mL/kg/min). This corresponded with the
mean (SD) change in peak power output from baseline
to 3 months, which was + 24W (17) for HIIT, + 12W
(16) for MICT, and + 4W (14) for control.
The interviewees reported a range of physical benefits
from participating in the exercise programmes, including
feeling fitter (n = 8) and more energised (n = 8), and
having a thinner waist (n = 1) and more-defined thigh
muscles (n = 2). Five participants also reported
disease-specific benefits, such as reduced inflammation
(n = 1; based on routine colonoscopy findings), less
frequent bowel movements (n = 1), and a “calmer gut”
(n = 1). Mental benefits were less frequently cited, but
included generally feeling better (n = 2), and improve-
ments in wellbeing (n = 3) and mood (n = 2). Eight par-
ticipants said that the study had increased their
motivation to exercise in the future, and 12 participants
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said that they had continued exercising (a variety of re-
gimes) since finishing the supervised sessions.
Disease activity and safety
Summary data for disease activity (CDAI and faecal cal-
protectin) are presented in Table 2.
Two participants, one from each exercise group, expe-
rienced disease relapse between baseline and 3months.
The HIIT participant was a 29-year-old male. His CDAI
score increased from 62 to 278 and faecal calprotectin
increased from 117 to > 400 μg/g. No medications were
recorded at baseline or follow-up. In his exit interview,
he referred to his stomach “going a bit funny but it not
being a complete flare” at approximately one third of the
way through the exercise programme. He thought that
this “mini flare” was related to stress and not the exer-
cise, and he was well enough to continue exercising,
completing 33 sessions. Further review of his results
show that a FC result done in the 6 months prior to
entry to the trial was > 400 μg/g. At the time of entry to
the trial he was on no medication having previously
been on anti-TNF which was stopped due to antibody
formation and clinical remission and his faecal calpro-
tectin was being monitored. It seems likely that the
in-trial flare occurred due to the progressive nature of
his disease whilst on no treatment. He has since started
on vedolizumab with a good response.
The MICT participant was a 37-year-old female. She
was stable on 15mg/week methotrexate at baseline but
and had switched to 50 mg/day azathioprine by 3
months due to troubling hair loss which she perceived
as a side effect of methotrexate. Within a few weeks of
that switch she was suffering symptoms of a relapse and
her faecal calprotectin was raised. She also developed
anaemia. Over the course of the trial her CDAI in-
creased from 38 to 181, and faecal calprotectin from 46
to > 400 μg/g. She completed 25 exercise sessions. Of
the missed sessions, six were missed due to ill health
(five of which due to virus/vomiting). In her exit inter-
view, she referred to feeling tired at the end of the super-
vised period, and she put this down to anaemia, which
she had only recently become aware of and received
treatment for. It seems possible that her relapse was re-
lated to her switch in medication. She was eventually
started on infliximab with a good response.
Four adverse events were also reported during the trial;
all within the HIIT group. Three were rated as non-serious
but exercise-related. One participant experienced a mild
headache and dizziness after exercise on two separate oc-
casions. After clinical review, these symptoms were
deemed to be related to dehydration-induced migraine.
The participant was re-informed about appropriate dietary
and hydration habits in relation to the exercise sessions.
After this, these symptoms no longer occurred. For the
other adverse event, one participant vomited 5min after
the end of a session. This was likely due to the participant
having eaten immediately before the session. The partici-
pant was re-informed about appropriate timing of
meals in relation to the exercise sessions. The final
adverse event was unrelated to the trial and
non-serious; a participant became ill with a chest in-
fection shortly after randomisation, resulting in them
missing all of their exercise sessions.
Discussion
A key finding of this pilot randomised controlled trial
was that the pre-specified criteria for progressing to a
full-scale trial of supervised exercise training in CD were
all satisfied. The minimum recruitment target was
achieved, and rates of exercise attendance and outcome
completion were good. Interview feedback about the ex-
ercise programmes was generally positive, with most
Table 2 Fitness and health measures at baseline and follow-up
HIIT MICT Control All
Body mass, kg
Baseline 76.2 (13.5) 63.8 (12.5) 69.8 (13.2) 70.1 (13.8)
3 months 76.4 (14.4) 63.0 (12.7) 71.0 (13.5) 70.1 (14.3)
Waist circumference, cm
Baseline 87.3 (11.8) 79.5 (14.7) 83.1 (9.8) 83.4 (12.4)
3 months 86.5 (9.8) 76.8 (12.8) 84.8 (8.5) 82.6 (11.1)
Resting heart rate, beats/min
Baseline 72 (8) 75 (12) 73 (11) 73 (10)
3 months 72 (10) 74 (9) 76 (10) 74 (10)
Systolic blood pressure, mmHg
Baseline 130 (12) 122 (17) 126 (13) 126 (14)
3 months 126 (11) 120 (16) 128 (15) 125 (14)
Diastolic blood pressure, mmHg
Baseline 82 (10) 76 (9) 78 (8) 79 (9)
3 months 78 (9) 74 (10) 79 (10) 77 (9)
Ventilatory threshold, mL/kg/min
Baseline 16.5 (4.9) 16.0 (4.1) 16.6 (6.1) 16.4 (4.9)
3 months 16.8 (5.5) 18.2 (3.7) 16.1 (4.7) 17.0 (4.7)
Peak oxygen uptake, mL/kg/min
Baseline 27.3 (7.7) 28.7 (8.6) 28.6 (10.0) 28.2 (8.6)
3 months 29.7 (8.2) 29.3 (6.6) 28.5 (9.2) 29.2 (7.9)
CDAI
Baseline 74 (48) 55 (47) 73 (45) 67 (46)
3 months 59 (74) 78 (48) 99 (50) 77 (59)
Faecal calprotectin, μg/g
Baseline 89 (72) 45 (40) 56 (55) 65 (59)
3 months 100 (113) 63 (113) 69 (146) 77 (121)
Data are presented as mean (SD)
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participants stating that they enjoyed attending and ex-
perienced fitness and health benefits. There were very
few exercise-related adverse events.
This is the first study to test and demonstrate the feasi-
bility and acceptability of HIIT in adults with CD. Several
trials have shown HIIT to be a safe and effective exercise
strategy in other clinical populations [13, 33, 34], but all
previous prospective studies in CD have investigated
low-to-moderate-intensity exercise programmes [7–11].
The reasons for this are unclear, but may include concerns
that high-intensity exercise will acutely exacerbate inflam-
mation and CD symptoms [4]. Such concerns are not sup-
ported by the current findings or other non-trial data.
Indeed, both our cycle-based HIIT and MICT pro-
grammes had good attendance figures and positive feed-
back, with no participant reporting exercise causing a
worsening of their symptoms. Interestingly, the majority
of participants had a pre-randomisation preference for
HIIT, suggesting that many patients want to exercise at a
high-intensity and are not fearful of doing so (at least
when under supervision and in a controlled environment).
In previous work, Ploeger et al. [17] demonstrated that a
single session of cycle-based HIIT was well-tolerated and
did not exacerbate inflammation or disease symptoms in
15 teenagers with CD. Similarly, a conference abstract
reporting a prospective study of seven adults with CD par-
ticipating in high-intensity continuous exercise events
such as triathlons, marathons, and long-distance bike
races showed no abnormal elevation of faecal calprotectin
measured at 24 h and one week after the event [35]. Five
of the seven patients also had no change in their symp-
toms or disease activity scores. The two remaining
Table 3 Questionnaire data at baseline and follow-up
HIIT MICT Control All
IBDQ (32 to 224)a
Baseline 184 (16) 181 (23) 164 (17) 177 (20)
3 months 186 (19) 192 (18) 174 (21) 184 (20)
6 months 180 (20) 189 (22) 175 (23) 182 (22)
EQ-5D (−0.285 to 1)a
Baseline 0.85 (0.13) 0.83 (0.12) 0.70 (0.20) 0.80 (0.16)
3 months 0.85 (0.10) 0.87 (0.13) 0.78 (0.17) 0.83 (0.14)
6 months 0.85 (0.12) 0.83 (0.12) 0.77 (0.22) 0.81 (0.16)
IBD-F, Fatigue (0 to 20)b
Baseline 8.2 (3.0) 7.8 (5.3) 9.3 (4.1) 8.4 (4.1)
3 months 8.3 (3.2) 8.3 (4.9) 7.8 (4.2) 8.1 (4.0)
6 months 7.5 (2.5) 7.3 (4.2) 7.5 (4.0) 7.4 (3.6)
IBD-F, Activities (0 to 120)b
Baseline 22.3 (19.0) 22.7 (22.5) 34.3 (20.5) 26.1 (20.8)
3 months 26.4 (20.5) 25.4 (28.1) 35.0 (20.4) 28.7 (23.1)
6 months 27.7 (12.4) 26.2 (20.6) 32.4 (21.3) 28.7 (18.4)
HADS, Anxiety (0 to 21)b
Baseline 5.5 (3.9) 6.8 (5.2) 7.7 (4.3) 6.6 (4.4)
3 months 5.2 (2.5) 5.5 (3.6) 6.2 (4.2) 5.6 (3.4)
6 months 3.8 (3.5) 5.3 (4.3) 5.5 (3.6) 4.9 (3.7)
HADS, Depression (0 to 21)b
Baseline 3.6 (3.1) 3.8 (2.9) 5.2 (2.9) 4.1 (3.0)
3 months 2.7 (1.7) 2.7 (3.3) 2.6 (2.5) 2.7 (2.5)
6 months 2.7 (1.5) 3.1 (3.1) 4.4 (4.0) 3.4 (3.1)
IPAQ, Total physical activity, MET-min/week, median (IQR)
Baseline 2874 (1273, 6474) 3237 (1383, 5442) 1602 (526, 2781) 2484 (1028, 4409)
3 months 3618 (1692, 5271) 2099 (1441, 3729) 2928 (2118, 5351) 2897 (1645, 5213)
6 months 1188 (99, 4149) 2163 (1328, 7993) 2817 (2243, 3969) 2557 (1109, 4451)
Data are presented as mean (SD) unless otherwise stated
aHigher score is better
bLower score is better
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patients showed elevated disease activity scores at 24 h
after exercise, with scores returning to baseline within one
week. Together, the available data appear promising
regarding the safety of cycle-based HIIT; however, lar-
ger prospective studies are needed before firm recom-
mendations can be made about the suitability of this
type of training.
The pre-specified criteria for planning a full-scale trial
were largely met. Sixty four percent of HIIT and MICT
participants attended at least 24 of the 36 sessions (the
aim was for at least 67%, this was achieved in MICT
group but not in HIIT). A total of 36 participants were
recruited over 17 months (mean 2.4 per month), with 27
randomised in the first 12 months. The 3-month re-
sponse rate exceeded 67%. We therefore plan to progress
to a full-scale trial, with some changes, that would have
a main aim of determining the efficacy and safety of su-
pervised exercise training in people with CD. The find-
ings from our pilot work have implications for this
future trial, and the proposed changes to study design
are summarised in Additional file 3. The main changes
relate to the intervention. Firstly, we plan to investigate
one exercise programme instead of two (i.e., change to a
2-arm, exercise versus control design). Although this will
remove the ability to compare different exercise pro-
grammes, it will simplify the design and make the re-
cruitment target more attainable. Secondly, we plan to
expand the exercise regime to include resistance and
flexibility exercises. The addition of resistance training,
the benefits of which we are currently investigating [36],
will ensure the programme aligns with global recom-
mendations on physical activity for health [37], and pro-
mote improvements in skeletal muscle function and
bone strength [38], both of which are commonly im-
paired in people with CD [3, 39, 40]. For the aerobic
component, we plan to use a mixture of HIIT and MICT
because of evidence that doing so increases the likeli-
hood of an improvement in cardiorespiratory fitness be-
ing observed [41], and that variety can support regular
attendance [42]. Offering sessions on weekends might
also improve attendance rates. This was not feasible in
the current study because the university facilities were
unavailable at weekends. For the future trial, we are ex-
ploring whether we could deliver the intervention in
community-based exercise facilities that are open 7 days
per week. Potential challenges include finding an exer-
cise venue to pair with each of the hospital sites, and en-
suring appropriate staffing.
Strengths of this study include blinded outcome as-
sessment, low rates of attrition and missing data, and ex-
ercise sessions being consistently delivered as planned
(when attended). The study did have some limitations,
however. Firstly, the intentionally small sample size
makes the study underpowered to assess efficacy, and
the upper target sample size of 45 was not achieved.
However, our preliminary data could be used in a
meta-analysis in the future. A second limitation was the
use of self-reported physical activity, which has been
shown to be inaccurate when compared with objective
measurement from devices such as accelerometers [43].
Thirdly, we did not use endoscopies to directly visualise
the effect of exercise on the gastrointestinal tract. These
two limitations can be addressed easily in the future trial
by using accelerometry and capsule endoscopic evalu-
ation, respectively. A fourth limitation was that partici-
pants were not blinded to group allocation during
follow-up, making the patient-reported outcomes sus-
ceptible to bias [44]. Using a control condition that
matches the exercise programme(s) for attention (e.g.,
flexibility or light resistance training) is a potential ap-
proach to minimising the risk of this bias. Finally, uncer-
tainty remains about how successful recruitment and
retention would be at other potential trial sites. Given
that many more sites would be required in a subsequent
trial, the continued monitoring of feasibility issues
through an internal pilot phase would be beneficial, par-
ticularly within the first year of recruitment.
Conclusion
In conclusion, cycle-based HIIT and MICT are feasible
and acceptable exercise strategies in adults with quiescent
or mildly-active CD. Larger-scale trials are needed to pro-
vide precise estimates of the benefits and harms of differ-
ent exercise programmes, and our findings suggest that a
multi-centre trial of supervised exercise training is feasible
in the UK. Physical exercise remains a potentially useful
adjunct therapy and lifestyle behaviour in CD.
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